Recombinant Mouse Interferon alpha/beta receptor 1 (Ifnar1)

What is mouse Interferon alpha/beta receptor 1 (Ifnar1)?

Mouse Interferon alpha/beta receptor 1 (IFNAR1) is a 100-130 kDa glycoprotein belonging to the class II cytokine receptor family. It functions as one subunit of the heterodimeric type I interferon receptor complex, which is essential for mediating cellular responses to type I interferons including IFN-α, IFN-β, and IFN-ω. As a transmembrane protein, IFNAR1 plays a crucial role in anti-microbial signal transduction when associated with its partner subunit IFNAR2 .

Mature mouse IFNAR1 has a complex structure consisting of a 403 amino acid extracellular domain (aa 27-429), a 20 amino acid transmembrane segment, and a 141 amino acid cytoplasmic domain that mediates downstream signaling events . IFNAR1 activation depends on multiple post-translational modifications, including tyrosine phosphorylation and palmitoylation of its cytoplasmic domain, which are essential for proper signal transduction .

What is the structure and composition of recombinant mouse Ifnar1?

Recombinant mouse IFNAR1 typically consists of the extracellular domain spanning amino acids Glu27-Thr429, often produced with a C-terminal tag (such as a His-tag) to facilitate purification and detection . The extracellular domain contains three tandem fibronectin type III repeats and is extensively glycosylated, which contributes to its proper folding and function .

Commercial preparations of recombinant mouse IFNAR1 protein are typically expressed in either baculovirus-infected insect cells or mammalian expression systems to ensure proper post-translational modifications, particularly glycosylation . These preparations generally achieve >90% purity with low endotoxin levels (<1 EU/μg), making them suitable for in vitro binding studies, neutralization assays, and as standards in detection methods like ELISA or Western blotting .

For research applications requiring carrier-free preparations, specially formulated versions without bovine serum albumin (BSA) are available. These carrier-free preparations are particularly useful for applications where the presence of BSA might interfere with experimental outcomes .

How do mouse and human Ifnar1 compare structurally and functionally?

While mouse and human IFNAR1 share fundamental roles in type I interferon signaling, they exhibit significant structural differences:

• Sequence homology: Mouse IFNAR1 extracellular domain shares only 47% amino acid identity with its human counterpart, while sharing 68% identity with rat IFNAR1 .

• Ligand binding characteristics: Both mouse and human IFNAR1 interact very weakly or not at all with type I interferons in isolation. Instead, they form stable ternary complexes following the initial association of interferons with IFNAR2 .

• Cross-reactivity: Due to the moderate sequence homology, most type I interferons exhibit species specificity, meaning human interferons typically show reduced activity on mouse cells and vice versa.

• Receptor signaling dynamics: Despite structural differences, both species' receptors engage similar downstream signaling pathways, primarily the JAK-STAT pathway, though with potential differences in signaling kinetics and intensity.

These structural differences have important implications for translational research, as findings from mouse models may not always directly translate to human biology, particularly when studying compounds that target the interferon receptor complex.

What experimental methods are used to assess recombinant Ifnar1 quality and activity?

Several methods are employed to evaluate the quality and functional activity of recombinant IFNAR1:

• Purity assessment: SDS-PAGE analysis confirms protein size and purity, typically aiming for >90% purity for research applications .

• Binding affinity measurements: Surface plasmon resonance (SPR) analysis can determine the kinetics of IFNAR1 binding to ligands or partner receptors. Engineered constructs like IFNAR1-FChk fusion proteins enable precise measurement of binding affinities that correlate well with cellular binding .

• Biological activity assays: Recombinant IFNAR1 can be tested for its ability to neutralize IFN-α-induced antiviral effects. The half-maximal inhibitory concentration (IC50) for this effect is typically 0.3-1.2 μg/mL when tested with 30 pg/mL of recombinant mouse Limitin/IFN-ζ .

• Glycosylation analysis: Mass spectrometry and lectin binding assays can be used to characterize the glycosylation pattern, which is critical for proper IFNAR1 folding and function.

• Endotoxin testing: Recombinant proteins should be tested for endotoxin contamination, with levels below 1 EU/μg considered acceptable for most research applications .

What reconstitution and storage protocols are recommended for recombinant mouse Ifnar1?

For optimal stability and activity of recombinant mouse IFNAR1:

• Reconstitution: Lyophilized protein should be reconstituted at a concentration of approximately 100 μg/mL in sterile PBS . For carrier-free preparations, reconstitution should be performed carefully to avoid denaturation.

• Storage conditions: Use a manual defrost freezer and avoid repeated freeze-thaw cycles to maintain protein integrity . Long-term storage at -80°C in small aliquots is recommended after reconstitution.

• Shipping: The product is typically shipped at ambient temperature but should be stored immediately upon receipt at the recommended temperature .

• Stability considerations: For preparation containing carrier proteins like BSA, increased shelf-life and stability at more dilute concentrations is observed compared to carrier-free versions .

• Working solutions: For experiments, freshly thawed aliquots should be used, kept on ice, and any unused portion should be discarded rather than refrozen.

How do mutations in IFNAR1 affect responses to different type I interferons?

Research has revealed fascinating differential effects of IFNAR1 mutations on responses to various type I interferons:

Human IFNAR1 variants have been identified that selectively impair responses to IFN-α and IFN-ω without affecting responses to IFN-β . This selective impairment has significant clinical implications, as patients heterozygous for these variants display increased susceptibility to viral diseases despite maintaining normal IFN-β responses .

Of particular interest is the P335del variant, which is common in Southern China (minor allele frequency ≈2%) . Cells heterozygous for this and other similar variants display a dominant phenotype in vitro with impaired responses to IFN-α and IFN-ω, but not IFN-β, leading to increased viral susceptibility .

These findings indicate that different type I interferons may engage the receptor complex through subtly different mechanisms, with IFN-β potentially utilizing alternative binding modes or receptor conformations that are less affected by certain mutations.

What methods can be used to analyze Ifnar1-ligand binding kinetics?

Advanced methodologies for analyzing IFNAR1-ligand interactions include:

• Engineered FC domain heterodimers: An engineered FC domain (FChk) that forms a covalent heterodimer can be used to create IFNAR1-FChk, IFNAR2-FCkh, and IFNAR1/IFNAR2-FChk fusion proteins . This system allows precise measurement of binary and ternary complex formation.

• Surface plasmon resonance (SPR) analysis: SPR can be used to measure binding kinetics of IFN interactions with individual receptor components and with the preformed receptor complex. Studies using this approach have shown that the affinity of IFNα2a for the IFNAR1/IFNAR2-FChk complex reproduces the affinity observed for IFNα2a binding to living cells .

• Cellular inhibition assays: The potency of IFNAR1/IFNAR2-FChk to neutralize IFNα2a bioactivity shows an inhibitory concentration equivalent to the KD measured by SPR, validating the physiological relevance of these in vitro binding measurements .

• Biolayer interferometry: This label-free technology can be used to measure biomolecular interactions in real-time, providing an alternative to SPR for kinetic analysis.

These methods have revealed that IFNAR1 interacts very weakly or not at all with type I interferons in isolation and does not stably interact with IFNAR2 alone . Instead, ligands preferentially associate with IFNAR2, and this complex subsequently forms a stable ternary assembly with IFNAR1 .

How does Ifnar1 contribute to immunosuppression in the tumor microenvironment?

IFNAR1 plays a complex and sometimes counterintuitive role in tumor immunology:

Studies of head and neck squamous cell carcinomas (HNSCC) have demonstrated that overexpression of IFNAR1, MX1, and STAT1 indicates endogenous IFNα activation in the tumor microenvironment, which correlates with immunosuppression status in patients .

Mechanistically, IFNα transcriptionally activates the expression of programmed death ligand 1 (PDL1) through phosphorylated STAT1 (Tyr701) and promotes programmed cell death protein 1 (PD1) expression in immune cells through IFNAR1 . These findings reveal a previously unappreciated immunosuppressive role for IFNα signaling.

Importantly, inhibition of IFNα signaling enhances the cytotoxic activity of natural killer cells, suggesting that blocking the IFNα pathway may enhance the efficacy of immune checkpoint blockade therapies .

This paradoxical effect—where a pathway typically associated with antiviral defense also contributes to tumor immunosuppression—highlights the context-dependent nature of cytokine signaling and suggests new therapeutic approaches targeting the IFN-IFNAR1 axis in cancer treatment.

What is the mechanism of negative dominance in IFNAR1 variants?

The negative dominance observed with certain IFNAR1 variants operates through several possible mechanisms:

• Receptor complex destabilization: Mutant IFNAR1 proteins may form unstable complexes with IFNAR2 and ligands, disrupting signaling even in the presence of wild-type IFNAR1.

• Selective ligand interference: Some variants specifically interfere with IFN-α and IFN-ω binding or signaling while preserving IFN-β responses . This suggests differential structural requirements for various type I IFNs.

• Dominant-negative signaling effects: Mutant IFNAR1 may recruit signaling molecules that actively inhibit the function of wild-type receptor complexes.

• Altered receptor trafficking or stability: Some variants might affect receptor turnover, internalization, or surface expression, thereby altering the availability of functional receptors.

Importantly, cells heterozygous for these IFNAR1 variants display a dominant phenotype in vitro with impaired responses to IFN-α and IFN-ω, while maintaining normal IFN-β responses . The clinical manifestation of this dominant effect is evident in patients heterozygous for these variants who display increased susceptibility to viral diseases including critical COVID-19 pneumonia, HSE, JEV encephalitis, and adverse reactions to live attenuated viral vaccines .

What experimental models are optimal for studying Ifnar1 function in vivo?

Several experimental models provide valuable insights into IFNAR1 function:

• Genetically modified mouse models:

  • Complete Ifnar1 knockout mice display profound defects in antiviral responses

  • Conditional knockout models allow tissue-specific deletion of Ifnar1

  • Knockin models expressing specific IFNAR1 variants can recapitulate human disease phenotypes

• Patient-derived xenograft (PDX) models: These have been used to confirm the upregulation of PDL1 and PD1 in response to IFNα treatment, validating findings from cell culture systems .

• Cell line studies: Both wild-type and engineered cell lines expressing IFNAR1 variants provide systems to dissect signaling mechanisms in controlled conditions.

• Human samples: Analysis of IFNAR1 expression and function in patients with viral diseases or cancer provides clinically relevant insights into receptor biology.

• Viral challenge models: Infection of IFNAR1-deficient or variant-expressing models with various viruses can reveal pathogen-specific dependencies on type I IFN signaling.

These complementary approaches allow researchers to investigate IFNAR1 function at multiple levels, from molecular interactions to whole-organism phenotypes and clinical outcomes.

What is the role of Ifnar1 in viral pathogenesis?

IFNAR1 is critical for antiviral defense, with deficiencies leading to increased susceptibility to multiple viral pathogens:

Patients with autosomal recessive deficiency of IFNAR1 or IFNAR2 show abolished cellular responses to IFN-α, -β, and -ω, resulting in severe viral diseases . These deficiencies are globally rare but show higher prevalence in specific populations, such as Western Polynesia for IFNAR1 deficiency and Arctic regions for IFNAR2 deficiency .

Even partial IFNAR1 deficiency, as observed in patients heterozygous for dominant negative variants, increases susceptibility to viral diseases including:

• Critical COVID-19 pneumonia

• Herpes simplex encephalitis (HSE)

• Japanese encephalitis virus (JEV) encephalitis

• Enterovirus 71 (EV71) encephalitis

• Adverse reactions to live attenuated vaccines, particularly MMR and Yellow Fever vaccines

The clinical profile of IFNAR1 deficiency resembles that seen in patients with auto-antibodies neutralizing type I IFNs, further validating the essential role of this signaling pathway in viral defense .

These findings highlight the importance of IFNAR1-mediated signaling in controlling viral replication and spread, particularly for neurotropic viruses and respiratory pathogens.

How can researchers optimize experimental design when working with recombinant Ifnar1?

To ensure robust and reproducible results when working with recombinant IFNAR1:

• Protein quality considerations:

  • Choose carrier-free preparations for applications where BSA might interfere

  • Verify protein quality through SDS-PAGE and activity assays before use

  • Monitor glycosylation status, as this affects receptor function

• Experimental controls:

  • Include both positive controls (known IFNAR1 ligands) and negative controls

  • For binding studies, use IFNAR2 preparations to distinguish receptor-specific effects

  • Consider species compatibility when designing experiments

• Concentration optimization:

  • Determine dose-response relationships for your specific application

  • For neutralization assays, the typical working range is 0.3-1.2 μg/mL

  • Account for protein loss during experimental procedures

• Storage and handling:

  • Prepare small, single-use aliquots to avoid freeze-thaw cycles

  • Maintain cold chain during experiments

  • Consider stabilizing additives for prolonged incubations

• Data interpretation:

  • Remember that IFNAR1 alone interacts weakly with IFNs; consider the IFNAR1/IFNAR2 complex

  • Account for species differences when extrapolating between mouse and human systems

  • Validate key findings with complementary approaches (e.g., both binding and functional assays)